Optimising migraine treatment: from drug-drug interactions to personalized medicine
Abstract Migraine is the most disabling and expensive chronic disorders, the etiology of which is still not fully known. The neuronal systems, (glutammatergic, dopaminergic, serotoninergic and GABA-ergic) whose functionality is partly attributable to genetically determined factors, has been suggeste...
Main Authors: | Leda Marina Pomes, Martina Guglielmetti, Enrico Bertamino, Maurizio Simmaco, Marina Borro, Paolo Martelletti |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | The Journal of Headache and Pain |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s10194-019-1010-3 |
Similar Items
-
CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
by: Matilde Capi, et al.
Published: (2021-04-01) -
New strategies for migraine treatment and prevention
by: Waldemar Brola, et al.
Published: (2019-10-01) -
Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
by: Damiana Scuteri, et al.
Published: (2021-09-01) -
Therapeutic novelties in migraine: new drugs, new hope?
by: Thien Phu Do, et al.
Published: (2019-04-01) -
Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
by: Danuta Szkutnik-Fiedler
Published: (2020-12-01)